Ulf Landmesser

Berlin, Germany

Why does the HDL particle give up during an acute coronary syndrome: The dysfunctional HDL syndrome Biological Function of HDL

Charité-Universitats medizin Berlin

Prof. Ulf Landmesser,  Professor and Chairman of Cardiology, Charité-Universitats medizin Berlin (Campus Benjamin Franklin).

Since October 1st 2014, Professor Ulf Landmesser acts as Chairman of the Department of Cardiology at the Charité – Universitätsmedizin Berlin (Campus Benjamin Franklin). He serves as Deputy Editor of the European Heart Journal, the leading cardiovascular journal in Europe, and as a member of the Executive Board of the European Association of Cardiovascular Prevention and Rehabilitation.
After his medical studies at the Medical School of Hannover, the University of Connecticut in Farmington (USA) and the National Heart&Lung Institute in London, he specialised in Internal Medicine and Cardiology at the Medical School of Hannover. In 2000/2001 he performed a post-doctoral fellowship at the Department of Cardiolo-gy at the Emory University School of Medicine, Atlanta (USA) as a scholar of the Al-exander von Humboldt Foundation. He received there the “Outstanding Fellows in Cardiology Special Recognition Award.” He was then appointed Consultant Cardiolo-gist at the Medical School of Hannover, Germany. In 2007, he was called as Senior Consultant Cardiologist of interventional and acute Cardiology and as Head of Cardi-ovascular Research of the Department of Cardiology at the University Hospital of Zürich, where he received the Götz Award in 2012, the official award of the medical fac-ulty of the University of Zurich for his research on coronary disease. Since 2010 he acted as Vice Chairman of the Department of Cardiology at the University Hospital of Zurich.
His research interest is focused on novel approaches to improve prevention and treatment of coronary disease. He has published more than 140 papers and received several research grants, including a transatlantic Leducq grant for a research network of excellence in cardiovascular disease and an EU-grant (Risky-CAD).

Stay up to date, subscribe to the newsletter

Progression and prevention of atherosclerosis and a translation to relevance.